Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC)1 Data for zongertinib monotherapy and in combination in other HER2-altered solid tumors, including breast, colorectal and esophageal cancers, shows encouraging early signals2-4 Updated […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.